Inxmed (Nanjing) Co. identifies new dual FAK inhibitors

May 20, 2026

Inxmed (Nanjing) Co. Ltd. has discovered new focal adhesion kinase (FAK) and focal adhesion kinase 2 (FADK2; PTK2B; PYK2) dual inhibitors potentially useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for May 20, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...